Size | Price | Stock | Qty |
---|---|---|---|
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
Other Sizes |
|
Purity: ≥98%
NBQX (also known as FG9202) is a novel, potent selective and competitive antagonist of aminomethylphosphonic acid receptor (AMPAR) with IC50 of 0.7 ± 0.1 μM. It has the potential to treat seizure. Brief NBQX administration during the 48 h postseizure in P10 Long-Evans rats suppresses transient mTOR pathway activation and attenuates spontaneous recurrent seizures, social preference deficits, and mossy fiber sprouting observed in vehicle-treated adult rats after early life seizures. These results suggest that acute AMPAR antagonist treatment during the latent period immediately following neonatal HS can modify seizure-induced activation of mTOR, reduce the frequency of later-life seizures, and protect against CA3 mossy fiber sprouting and autistic-like social deficits.
ln Vitro |
While NBQX disodium (FG9202 disodium) has little to no affinity for the glutamate recognition site on the NMDA receptor complex, it has a significant affinity for the AMPA and kainate binding sites [1].
|
---|---|
ln Vivo |
PTZ-induced seizures are lessened by NBQX disodium (FG9202; 20 mg/kg, i.p.; for 3 days) [2]. When given as an intravenous bolus dose of 30 mg/kg at the time of MCA blockage and again an hour later, NBQX disodium exerts neuroprotective benefits in a rat model of localized ischemia [1].
|
Animal Protocol |
Animal/Disease Models: Male Wistar rats, body weight 220-240 g, Pentylenetetrazole (PTZ) [2]
Doses: 20 mg/kg Route of Administration: intraperitoneal (ip) injection; 3 days Experimental Results: Effective reversal of chronic PTZ administration in rats (50 mg/kg; intraperitoneal; for 28 days) causing seizures and behavioral abnormalities. |
References |
[1]. Fukushima K, et al. Characterization of Human Hippocampal Neural Stem/Progenitor Cells and Their Application to Physiologically Relevant Assays for Multiple Ionotropic Glutamate Receptors. J Biomol Screen. 2014 Sep; 19(8):1174-84.
[2]. Wen Chen, et al. AMPA Receptor Antagonist NBQX Decreased Seizures by Normalization of Perineuronal Nets. PLoS One. 2016 Nov 23;11(11):e0166672. |
Molecular Formula |
C12H7N4NAO6S
|
---|---|
Molecular Weight |
380.24384
|
CAS # |
479347-86-9
|
Related CAS # |
NBQX;118876-58-7
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
O=S(C1=C2C(C3=C([N-]C(C([N-]3)=O)=O)C=C2[N+]([O-])=O)=CC=C1)(N)=O.[Na+].[Na+]
|
InChi Key |
XFHCQLPOJLVQQE-UHFFFAOYSA-L
|
InChi Code |
InChI=1S/C12H8N4O6S.2Na/c13-23(21,22)8-3-1-2-5-9(8)7(16(19)20)4-6-10(5)15-12(18)11(17)14-6/h1-4H,(H4,13,14,15,17,18,21,22)/q2*+1/p-2
|
Chemical Name |
sodium 6-nitro-2,3-dioxo-7-sulfamoyl-2,3-dihydrobenzo[f]quinoxaline-1,4-diide
|
Synonyms |
NBQX disodium FG9202 FG-9202 FG 9202
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
---|---|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.6299 mL | 13.1496 mL | 26.2992 mL | |
5 mM | 0.5260 mL | 2.6299 mL | 5.2598 mL | |
10 mM | 0.2630 mL | 1.3150 mL | 2.6299 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.